Wang Yuqiang, Cao Tingqian, Liu Xiang, He Siyu, Ran Zechao, Du Chunlin, Lu Beiyao, Liu Yahui, Shi Jun, Liu Lulu, Zhou Yongzhao, Guo Yingqiang
Department of Cardiovascular Surgery and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.
Cardiovascular Surgery Research Laboratory, West China Hospital, Sichuan University, Chengdu, China; Department of Integrated Care Management Center, West China Hospital, Sichuan University, Chengdu, China.
JACC Asia. 2025 May;5(5):609-632. doi: 10.1016/j.jacasi.2025.01.017. Epub 2025 Apr 8.
Valvular heart disease (VHD) is rapidly increasing in prevalence worldwide, affecting millions and significantly impacting global health care systems. Despite notable advancements in understanding VHD progression, perioperative management, imaging techniques, and transcatheter therapies over the past 2 decades, the condition has not received the attention it deserves from the public and policymakers. Many patients with VHD in low- and middle-income countries continue to experience low detection, intervention, and follow-up rates. Systematic care for elderly patients and those with severe comorbidities, as well as postoperative patients, remains insufficient, leading to higher mortality and morbidity rates. This review focuses on the deficiencies in VHD treatment within the Chinese health care system and discusses the modern management program, known as the whole-life cycle management system, that has been implemented to enhance the survival prognosis of VHD patients.
心脏瓣膜病（VHD）在全球的患病率正在迅速上升，影响着数百万人，并对全球医疗保健系统产生重大影响。尽管在过去20年里，在了解VHD进展、围手术期管理、成像技术和经导管治疗方面取得了显著进展，但这种疾病尚未得到公众和政策制定者应有的关注。低收入和中等收入国家的许多VHD患者的检测、干预和随访率仍然很低。对老年患者、患有严重合并症的患者以及术后患者的系统护理仍然不足，导致更高的死亡率和发病率。本综述重点关注中国医疗保健系统中VHD治疗的不足之处，并讨论为提高VHD患者的生存预后而实施的现代管理方案，即全生命周期管理系统。
